HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Antony Loebel Selected Research

ziprasidone (Geodon)

6/2015A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.
1/2012A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
11/2011Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
4/2011Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
8/2010A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
9/2009Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
5/2009Weight effects associated with antipsychotics: a comprehensive database analysis.
1/2009A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
10/2008Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
7/2008Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Antony Loebel Research Topics

Disease

33Schizophrenia (Dementia Praecox)
01/2016 - 02/2004
9Weight Gain
11/2015 - 01/2007
9Psychotic Disorders (Schizoaffective Disorder)
08/2014 - 04/2006
7Bipolar Disorder (Mania)
11/2015 - 01/2007
5Psychomotor Agitation (Akathisia)
02/2014 - 09/2011
4Nausea
02/2014 - 05/2012
3Major Depressive Disorder (Major Depressive Disorders)
06/2015 - 07/2007
2Weight Loss (Weight Reduction)
11/2015 - 05/2009
2Body Weight (Weight, Body)
08/2014 - 02/2013
2Headache (Headaches)
02/2014 - 05/2012
2Sleep Initiation and Maintenance Disorders (Insomnia)
02/2014 - 05/2012
2Movement Disorders (Movement Disorder)
10/2008 - 01/2007
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
12/2015
1Overweight
11/2015
1Tremor (Tremors)
02/2014

Drug/Important Bio-Agent (IBA)

28N- (2- (4- (1,2- benzisothiazol- 3- yl)- 1- piperazinylmethyl)- 1- cyclohexylmethyl)- 2,3- bicyclo(2.2.1)heptanedicarboximideIBA
01/2016 - 06/2009
18ziprasidone (Geodon)FDA Link
06/2015 - 02/2004
11Antipsychotic Agents (Antipsychotics)IBA
01/2015 - 02/2004
8quetiapine (Seroquel)FDA Link
11/2015 - 04/2013
6Risperidone (Risperdal Consta)FDA LinkGeneric
11/2015 - 02/2004
5olanzapine (Zyprexa)FDA Link
05/2013 - 02/2004
4Glucose (Dextrose)FDA LinkGeneric
08/2014 - 09/2009
4Haloperidol (Haldol)FDA LinkGeneric
08/2010 - 04/2006
3ProlactinIBA
08/2014 - 01/2009
2Insulin (Novolin)FDA Link
08/2014 - 02/2013
2LipidsIBA
08/2014 - 02/2013
2Triglycerides (Triacylglycerol)IBA
02/2014 - 09/2009
2CholesterolIBA
02/2014 - 09/2009
1Antidepressive Agents (Antidepressants)IBA
06/2015
1LithiumIBA
01/2015
1Valproic Acid (Valproate, Semisodium)FDA LinkGeneric
01/2015
1LDL CholesterolIBA
02/2014
1olanzapine-fluoxetine combination (Symbyax)FDA Link
02/2014
1Dopamine (Intropin)FDA LinkGeneric
09/2013
1A 7 (A-7)IBA
05/2009
1aripiprazole (Abilify)FDA Link
11/2007